In this episode of The GLP-1 Podcast Show, I speak with Dr. Timothy Garvey, Endowed Professor of Medicine at the University of Alabama at Birmingham, about complication-centric care for Adiposity-Based Chronic Disease. We examine current obesity guidelines, medication selection according to complications, what the key unmet clinical need is in obesity care, and the role of second-generation GLP-1 medications in type 2 diabetes. Listen now on all major platforms.

"Obesity treatment should focus on improving complications, quality of life, and health, not simply reaching a target amount of weight loss."

Meet the guest: Dr. Timothy Garvey is Endowed Professor and University Professor of Medicine at the University of Alabama at Birmingham. An endocrinologist specializing in obesity and type 2 diabetes, he has authored more than 380 publications and helped establish Adiposity-Based Chronic Disease as a diagnostic framework while leading major obesity guidelines. Listen to Dr. W. Timothy Garvey on The GLP-1 Podcast Show, available on all major platforms.

Want to stay up to date on the latest GLP-1 research and updates? Subscribe and never miss an episode.

What you will learn:

• (00:00) Highlight
• (02:14) Introduction
• (07:17) Clinical guidelines
• (10:35) Complication care
• (15:34) Medication selection
• (20:39) Disease evidence
• (29:40) Diabetes management
• (33:22) Closing thoughts

The GLP-1 Podcast Show is trusted and supported by innovative companies like:

- ZentrixOS

- Zentrix Insights

- Elevate

- WiseVAs

𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺.

Website: The GLP-1 Podcast Show

Instagram: The GLP-1 Podcast Show

LinkedIn: The GLP-1 Podcast Show

YouTube: The GLP-1 Podcast Show

Facebook: The GLP-1 Podcast Show

TikTok: The GLP-1 Podcast Show

In this episode of The GLP-1 Podcast Show, I speak with Dr. Christopher Kramer, Chief of the Cardiovascular Division at the University of Virginia Health, about how GLP-1 and GIP therapies are reshaping the treatment of obesity-related heart failure. We explore cardiac remodeling, adipose tissue reduction, cardiovascular outcomes, and the mechanisms behind improved patient health. Listen now on all major platforms!

"Treatment with tirzepatide reduced heart failure events by approximately fifty percent while helping patients feel better and perform daily activities more comfortably."

Meet the guest: Dr. Christopher Kramer earned his A.B. from Harvard and his M.D. from UCSF before completing cardiology training at the University of Pennsylvania. He is the George A. Beller, MD/Lantheus Medical Imaging Distinguished Professor of Cardiovascular Medicine and Chief of the Cardiovascular Division at the University of Virginia Health. His research focuses on cardiovascular magnetic resonance imaging and heart disease. Listen to Dr. Christopher Kramer on The GLP-1 Podcast Show, available on all major platforms.

What you will learn:

• (00:00) Highlight
• (01:40) Introduction
• (09:16) Heart failure outcomes
• (17:55) Cardiac adipose reduction
• (23:01) Ventricular remodeling
• (27:42) Weight loss benefits
• (30:18) Future triple agonists
• (31:36) Final Questions

The GLP-1 Podcast Show is trusted and supported by innovative companies like:

- Elevate

- WiseVAs

- ZentrixOS

- Zentrix Insights

𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺.

Website: The GLP-1 Podcast Show

Instagram: The GLP-1 Podcast Show

LinkedIn: The GLP-1 Podcast Show

YouTube: The GLP-1 Podcast Show

Facebook: The GLP-1 Podcast Show

TikTok: The GLP-1 Podcast Show

In this episode of The GLP-1 Podcast Show, I speak with Dr. Richard DiMarchi, Distinguished Professor at Indiana University and a pioneer in peptide therapeutics, about the scientific journey behind GLP-1 therapies, multiagonist drug development, and future obesity treatments. We explore glucagon, GIP, triple agonists, and emerging innovations shaping metabolic medicine. Listen now on all major platforms!

"For decades, glucagon was viewed primarily as a hormone that raises blood glucose. Research later revealed that glucagon could also promote weight reduction and improve liver metabolism when balanced appropriately with GLP-1 activity."

Meet the guest: Dr. Richard DiMarchi is a Distinguished Professor at Indiana University and a recognized leader in peptide therapeutics, diabetes research, and obesity medicine. His work contributed to major advances in insulin, glucagon, and multiagonist therapies, while also helping establish several biotechnology companies. Dr. DiMarchi continues to advance innovation in the treatment of metabolic diseases through research and translational science. Listen to Dr. Richard DiMarchi on The GLP-1 Podcast Show, available on all major platforms.

What you will learn:

• (00:00) Highlight
• (01:19) Introduction
• (05:31) GLP-1 evolution
• (09:16) Multiagonist design
• (15:46) Glucagon controversy
• (17:42) GIP role
• (24:32) Future treatments
• (30:13) Final Questions

𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺.

Website: The GLP-1 Podcast Show

Instagram: The GLP-1 Podcast Show

LinkedIn: The GLP-1 Podcast Show

YouTube: The GLP-1 Podcast Show

Facebook: The GLP-1 Podcast Show

TikTok: The GLP-1 Podcast Show

In this episode of The GLP-1 Podcast Show, I speak with Dr. Sandra Christensen, obesity medicine specialist and founder of Integrative Medical Weight Management. We examine how GLP-1 therapies impact body composition beyond total weight loss. Dr. Christensen explores fat-free mass reduction, muscle and bone considerations, and clinical risks. She also addresses nutrition strategies, resistance training, and the importance of structured monitoring and personalized care. Listen now on all major platforms!

"When evaluating weight reduction outcomes, it is essential to distinguish between fat mass and fat-free mass, because each component has different physiological roles and clinical implications."

Meet the guest: Dr. Sandra Christensen is an obesity medicine specialist and founder of Integrative Medical Weight Management in Seattle. She holds advanced certification in obesity medicine and serves as a trustee for the Obesity Medicine Association and president of the Washington Obesity Society. Her work focuses on clinical strategies, patient care, and education in obesity treatment. Learn more from Dr. Sandra Christensen on The GLP-1 Podcast Show, available on all major platforms.

What you will learn:

• (00:00) Highlight
• (01:07) Introduction
• (02:34) Body composition
• (04:09) Fat-free mass
• (07:46) Protein strategies
• (12:08) Resistance training
• (14:51) Monitoring tools
• (25:47) Final Questions

𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺.

Website: The GLP-1 Podcast Show

Instagram: The GLP-1 Podcast Show

LinkedIn: The GLP-1 Podcast Show

In this episode of The GLP-1 Podcast Show, I speak with Dr. Jason Itri, Founder of Longevity Health Clinic, about how GLP-1 therapies extend beyond weight loss into cardiometabolic optimization. We examine microdosing strategies, insulin resistance, inflammation pathways, and sustainable habit formation through precision prescribing. Dr. Itri highlights practical clinical applications for long-term metabolic health. Listen now on all major platforms!

"Lower dose GLP-1 strategies can improve control over dietary habits by reducing impulsive food decisions and supporting consistent behavioral patterns over extended periods."

Meet the guest: Dr. Jason Itri is a physician and the founder of Longevity Health Clinic in Virginia, specializing in cardiometabolic health, hormone optimization, and GLP-1 therapies. His work integrates biomarker testing with root-cause physiology to improve metabolic outcomes and reduce long-term disease risk. His clinical focus aligns with advancing precision approaches in obesity medicine and metabolic care. 

What you will learn:

• (00:00) Highlight
• (01:08) Introduction
• (05:09) Microdosing strategy
• (07:27) Habit control
• (15:11) Risk markers
• (17:11) Insulin resistance
• (29:10) Muscle loss
• (32:20) Final Questions

𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺.

Website: The GLP-1 Podcast Show

Instagram: The GLP-1 Podcast Show

LinkedIn: The GLP-1 Podcast Show

In this episode of The GLP-1 Podcast Show, I speak with Dr. Catherine Toomer, founder of Total Weight Care Institute and a family medicine physician specializing in metabolic disease. The discussion examines long-term clinical experience using GLP-1 therapies, including dosing strategies, metabolic regulation, and patient-centered obesity care. She also explores insulin resistance, brain signaling, and emerging therapeutic applications. Listen now on all major platforms!

“Appetite regulation is strongly influenced by brain signaling pathways, and correcting metabolic signaling often changes hunger perception and eating behavior without relying on willpower alone.”

Meet the guest: Dr. Catherine Toomer is a family medicine physician and founder of Total Weight Care Institute, with more than fifteen years of clinical experience using GLP-1 therapies to address metabolic disease and obesity. Her work focuses on correcting metabolic dysregulation through evidence-based medical strategies and personalized care. 

What you will learn:

• (00:00) Highlight
• (00:31) Introduction
• (01:52) Metabolic disease drivers
• (05:33) Personalized dosing strategy
• (07:17) Managing side effects
• (19:44) Brain appetite signaling
• (22:40) Future applications
• (24:50) Final Questions

𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺.

Website: The GLP-1 Podcast Show

Instagram: The GLP-1 Podcast Show

LinkedIn: The GLP-1 Podcast Show

In this episode of The GLP-1 Podcast Show, I speak with Dr. Caroline Apovian, Professor of Medicine at Harvard Medical School and Co Director of the Center for Weight Management and Wellness at Brigham and Women’s Hospital, about the evolution of obesity treatment. We discuss why obesity is a chronic disease, how GLP-1 based therapies have changed clinical outcomes, and how they compare with lifestyle intervention and metabolic surgery. Dr. Apovian also addresses stigma, access barriers, and the risks of cosmetic use. Listen now on all major platforms!

"Stigma surrounding obesity has forced clinicians to repeatedly prove that treating obesity also prevents cardiovascular disease and diabetes."

Meet the guest: Dr. Caroline Apovian is Professor of Medicine at Harvard Medical School and Co Director of the Center for Weight Management and Wellness at Brigham and Women’s Hospital. A founding leader in obesity medicine, her research focuses on adipose tissue inflammation, cardiovascular risk, metabolic surgery, and pharmacotherapy for obesity. 

To hear Dr. Allison's actual remarks, view the recorded debate here!

What you will learn:

• (00:00) Highlight
• (01:23) Introduction
• (04:41) GLP-1 overview
• (07:55) Obesity disease model
• (13:35) Treatment comparisons
• (19:59) Cardiovascular outcomes
• (25:44) Cosmetic use debate
• (33:22) Final Questions

𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺.

Website: The GLP-1 Podcast Show

Instagram: The GLP-1 Podcast Show

LinkedIn: The GLP-1 Podcast Show

In this episode of The GLP-1 Podcast Show, I speak with Melissa Mitri, Registered Dietitian and weight loss expert at Melissa Mitri Nutrition, about real-world nutrition strategies for patients using GLP-1 therapies. She focuses on nutrient density, meal structure, side effect management, muscle preservation, and long-term habit building. Melissa shares clinical insights from nearly two decades of practice working directly with patients. Melissa highlights how nutrition and lifestyle optimize outcomes alongside GLP-1 medications. Listen now on all major platforms!

“GLP-1 therapies shift nutrition counseling away from calorie obsession toward nutrient density, because patients eat smaller portions and every bite must support metabolic health.”

Meet the guest: Melissa Mitri, MS, RD, is a Registered Dietitian, weight loss expert, and founder of Melissa Mitri Nutrition. She specializes in sustainable weight management, including nutrition support for patients using GLP-1 therapies. With nearly 20 years of clinical experience, her work focuses on nutrient density, habit formation, and evidence based care. 

Connect with our guest on Social Media:

LinkedIn

Instagram

GLP-1 Cheat Sheet for Clinicians

What you will learn:

• (00:00) Highlight
• (00:45) Introduction
• (02:27) Nutrition approach
• (04:59) Meal timing
• (07:23) Side effects
• (12:14) Muscle preservation
• (17:35) Long-term habits
• (29:49) Final Questions

𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺.

Website: The GLP-1 Podcast Show

Instagram: The GLP-1 Podcast Show

LinkedIn: The GLP-1 Podcast Show

In this episode of The GLP-1 Podcast Show, I speak with Dr. Ken Fujioka, Clinical Professor of Medicine and Director of the Nutrition and Metabolic Research Center at Scripps Clinic, about the clinical evolution of GLP-1-based therapies. He covers next-generation dual and triple agonists, dose titration, nausea management, and long-term weight maintenance. Dr. Fujioka also examines oral alternatives, safety concerns, and real-world prescribing considerations. Listen now on all major podcast platforms!

"Combining multiple satiety hormones allows greater weight reduction by targeting complementary brain and gastrointestinal pathways involved in appetite regulation."

Meet the guest: Dr. Ken Fujioka is a Clinical Professor of Medicine and Director of the Nutrition and Metabolic Research Center at Scripps Clinic, specializing in obesity, diabetes, and metabolic disease management. His work focuses on clinical trials, patient-centered weight treatment, and GLP-1-based therapies.

What you will learn:

• (00:00) Highlight
• (00:57) Introduction
• (02:59) New GLP-1 agents
• (05:12) Dose titration
• (08:14) Glucagon role
• (10:29) Clinical precautions
• (12:53) Oral alternatives
• (22:42) Final Questions

𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺.

Website: The GLP-1 Podcast Show

Instagram: The GLP-1 Podcast Show

LinkedIn: The GLP-1 Podcast Show

In this episode of The GLP-1 Podcast Show, I speak with Dr. Jens Juul Holst, Professor of Medical Physiology at the University of Copenhagen and Senior Group Leader at the Novo Nordisk Foundation Center for Basic Metabolic Research. We explore the discovery of GLP-1, its evolution into today’s leading therapies for diabetes and obesity, and the molecular and clinical mechanisms that drive their success. Listen now on all major platforms.

“The incretin hormones GLP-1 and GIP amplify insulin secretion after meals, ensuring glucose tolerance and maintaining energy balance across multiple tissues.”

Meet the guest: Dr. Jens Juul Holst is Professor of Medical Physiology at the University of Copenhagen and Senior Group Leader at the Novo Nordisk Foundation Center for Basic Metabolic Research. His research focuses on metabolic hormones, appetite regulation, and the pathophysiology of obesity and type 2 diabetes. Known for co-discovering GLP-1, his work has shaped modern metabolic therapy. 

What you will learn:

• (00:00) Highlight
• (00:58) Introduction
• (02:07) GLP-1 mechanism
• (05:00) Discovery process
• (07:35) Therapeutic development
• (11:19) Cardiovascular effects
• (15:08) Broader metabolic impact
• (20:27) Final Questions

𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺.

Website: The GLP-1 Podcast Show

Instagram: The GLP-1 Podcast Show

LinkedIn: The GLP-1 Podcast Show